<DOC>
	<DOCNO>NCT00988897</DOCNO>
	<brief_summary>Primary Objective : - To demonstrate re-challenge oxaliplatin base regimen ( modify FOLFOX-6 ) provide clinical disease control rate ( DCR ) least 20 % end chemotherapy . Secondary Objective : - To evaluate measure tumour 's response safety .</brief_summary>
	<brief_title>Colorectal Cancer RECHALLENGE</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Inclusion criterion : Histologically prove adenocarcinoma colon rectum Measurable metastatic disease , either inoperable , residual surgical procedure No prior chemotherapy metastatic disease For colon cancer : prior adjuvant chemotherapy oxaliplatin end least 12 month prior enrollment . For rectal cancer : least 12 month since prior use oxaliplatin neoadjuvant adjuvant chemotherapy Adequate liver kidney function : Total bilirubin inferior 1.5 ULN Serum Creatinine inferior 150 umol/L Creatinine clearance ( ClCr ) &gt; 30 mL/min ALT / AST inferior 3 ULN Adequate hematological function Neutrophils &gt; equal 1.5 x 109/L Platelets &gt; equal 100 x 109/L Exclusion criterion : Metastatic disease present without prior adjuvant chemotherapy Metastatic disease present nonoxaliplatincontaining adjuvant chemotherapy Peripheral sensory motor neuropathy &gt; grade 1 Eastern Cooperative Oncology Group ( ECOG ) Performance status &gt; 2 Other active malignancy History know allergy oxaliplatin platinum compound , 5FU , Leucovorin ingredient formulation container Patients pregnant , breastfeed Patients severe renal impairment ( ClCr &lt; 30 mL/min ) Pernicious anemia megaloblastic anemia Vitamin B12 deficiency Patients reproductive potential implementing accept effective method contraception ( definition effective method contraception base investigator ' judgment ) Participation another clinical trial investigational drug within 30 day prior study screen For patient receive Bevacizumab : Bevacizumab contraindicate patient know hypersensitivity component product Chinese hamster ovary cell product recombinant human humanize antibody Presence symptom suggest brain metastasis The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>